Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 8, Issue 7, pp. 1725-1738
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 19, 2008
- Revision received April 21, 2009
- Accepted May 4, 2009
- Published first July 7, 2009.
Article Versions
- Previous version (July 7, 2009 - 08:43).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2009 American Association for Cancer Research.
Author Information
- Florence I. Raynaud1,
- Suzanne A. Eccles1,
- Sonal Patel2,
- Sonia Alix1,
- Gary Box1,
- Irina Chuckowree2,
- Adrian Folkes2,
- Sharon Gowan1,
- Alexis De Haven Brandon1,
- Francesca Di Stefano1,
- Angela Hayes1,
- Alan T. Henley1,
- Letitia Lensun2,
- Giles Pergl-Wilson2,
- Anthony Robson2,
- Nahid Saghir2,
- Alexander Zhyvoloup2,
- Edward McDonald1,
- Peter Sheldrake1,
- Stephen Shuttleworth2,
- Melanie Valenti1,
- Nan Chi Wan2,
- Paul A. Clarke1 and
- Paul Workman1
- 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow and McElwain Laboratories, Sutton, Surrey, United Kingdom and 2Piramed Pharma, Slough, Berkshire, United Kingdom
- Requests for reprints:
Florence Raynaud and Paul Workman, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom. Phone: 44-0-20-8722-4301; Fax: 44-0-20-8722-4324. E-mail: florence.raynaud{at}icr.ac.uk and paul.workman{at}icr.ac.uk
July 2009
Volume 8, Issue 7
Volume 8, Issue 7
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Jump to section
Advertisement